Double maintains 2 strategies that include STOK - Stoke Therapeutics, Inc.
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| XBI | 56.60% | $4.82B | 0.35% |
| GNOM | 53.71% | $44.57M | 0.5% |
| IBB | 52.65% | $5.26B | 0.45% |
| ARKG | 50.83% | $1.02B | 0.75% |
| PBE | 48.67% | $223.19M | 0.58% |
| PTH | 47.19% | $100.85M | 0.6% |
| IWC | 46.40% | $818.14M | 0.6% |
| FBT | 45.24% | $1.01B | 0.54% |
| BBH | 44.64% | $330.62M | 0.35% |
| XPH | 44.51% | $147.96M | 0.35% |
| IWO | 42.78% | $11.60B | 0.24% |
| VTWO | 42.06% | $12.52B | 0.07% |
| IWM | 42.04% | $63.72B | 0.19% |
| KJUL | 41.58% | $119.50M | 0.79% |
| SCHA | 40.92% | $17.26B | 0.04% |
| KJAN | 40.63% | $287.30M | 0.79% |
| NUSC | 40.50% | $1.14B | 0.31% |
| PRFZ | 40.50% | $2.36B | 0.34% |
| PINK | 40.34% | $130.57M | 0.5% |
| ISCG | 40.14% | $681.20M | 0.06% |
Current Value
$11.581 Year Return
Current Value
$11.581 Year Return
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| VIXY | -34.75% | $164.54M | 0.85% |
| TAIL | -29.06% | $99.63M | 0.59% |
| BTAL | -28.59% | $296.22M | 1.43% |
| IVOL | -12.33% | $347.03M | 1.02% |
| TFLO | -11.89% | $6.82B | 0.15% |
| CTA | -8.60% | $1.06B | 0.76% |
| PSQA | -8.23% | $35.44M | 0.2% |
| UUP | -7.98% | $201.63M | 0.77% |
| UNG | -7.94% | $360.54M | 1.06% |
| CLIP | -7.82% | $1.51B | 0.07% |
| FXY | -7.71% | $816.38M | 0.4% |
| ULST | -7.66% | $654.75M | 0.2% |
| USDU | -6.79% | $162.43M | 0.5% |
| VTIP | -6.61% | $15.33B | 0.03% |
| DBE | -6.33% | $52.20M | 0.77% |
| USO | -6.03% | $1.13B | 0.6% |
| STPZ | -5.93% | $450.47M | 0.2% |
| GBIL | -5.75% | $6.37B | 0.12% |
| BNO | -5.44% | $103.79M | 1% |
| STIP | -5.02% | $12.72B | 0.03% |
SeekingAlpha
Baker Brothersâ Q1 2025 portfolio reveals biotech investment trends. See more on their top holdings, stake changes, and high-conviction strategies.
Yahoo
BEDFORD, Mass., June 17, 2025--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on June 16, 2025, it granted stock options to purchase an aggregate of 37,200 shares of common stock to two new em
SeekingAlpha
Stoke Therapeutics advances RNA-based therapies for rare diseases like Dravet Syndrome.
Yahoo
BEDFORD, Mass., May 29, 2025--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that Interim Chief Executive Officer Ian F. Smith will present at the Jefferies Global Healthcare Conference on Wednesday, June 4,
Yahoo
The consensus price target hints at a 132.4% upside potential for Stoke Therapeutics (STOK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Yahoo
Stoke Therapeutics (STOK) delivered earnings and revenue surprises of 613.51% and 1,391.01%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CBOE | -15.30% | $24.23B | +35.36% | 1.09% |
| PRT | -11.85% | $49.39M | +3.31% | 10.74% |
| LITB | -9.97% | $21.24M | -78.57% | 0.00% |
| K | -9.81% | $27.76B | +41.17% | 2.85% |
| PRPO | -8.82% | $17.08M | +125.94% | 0.00% |
| VZ | -7.69% | $183.79B | +6.01% | 6.18% |
| NEUE | -6.77% | $61.24M | +29.92% | 0.00% |
| T | -5.57% | $203.71B | +51.55% | 3.92% |
| EXC | -4.49% | $43.33B | +23.58% | 3.62% |
| PSQH | -3.50% | $98.82M | -36.55% | 0.00% |
| HUSA | -3.08% | $19.66M | -19.53% | 0.00% |
| CNX | -2.90% | $4.69B | +30.63% | 0.00% |
| AIFU | -2.86% | $6.79B | +102.19% | 0.00% |
| COR | -2.85% | $56.44B | +30.86% | 0.74% |
| AQB | -2.46% | $2.96M | -53.35% | 0.00% |
| ED | -2.23% | $36.00B | +12.64% | 3.34% |
| STG | -2.16% | $30.78M | -22.51% | 0.00% |
| CREG | -1.91% | $5.77M | -79.16% | 0.00% |
| PINC | -1.48% | $1.79B | +18.29% | 3.85% |
| OCFT | -1.45% | $267.49M | +332.74% | 0.00% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| TIPX | -0.10% | $1.74B | 0.15% |
| BUXX | 0.18% | $315.18M | 0.25% |
| BILS | -0.19% | $3.81B | 0.1356% |
| KMLM | -0.28% | $188.90M | 0.9% |
| UGA | -0.35% | $72.33M | 0.97% |
| LDUR | -0.43% | $929.65M | 0.5% |
| USCI | -0.46% | $241.75M | 1.07% |
| CARY | 0.49% | $347.36M | 0.8% |
| BSMW | 0.51% | $107.45M | 0.18% |
| IBTI | 0.67% | $1.06B | 0.07% |
| CERY | 0.74% | $458.93M | 0.28% |
| FMHI | 0.76% | $754.85M | 0.7% |
| MMIN | 0.78% | $336.10M | 0.3% |
| VGSH | 0.81% | $22.80B | 0.03% |
| BIL | -0.82% | $42.24B | 0.1356% |
| KBA | 0.85% | $174.95M | 0.56% |
| CNYA | -0.86% | $195.82M | 0.6% |
| ASHR | -0.88% | $1.91B | 0.65% |
| SGOV | -0.89% | $49.21B | 0.09% |
| BSMR | -0.89% | $255.87M | 0.18% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| IDYA | 52.39% | $1.92B | -34.15% | 0.00% |
| NRIX | 51.01% | $948.37M | -35.91% | 0.00% |
| IMNM | 50.73% | $750.92M | -28.80% | 0.00% |
| RNA | 50.33% | $3.54B | -21.10% | 0.00% |
| DNLI | 50.00% | $2.16B | -30.05% | 0.00% |
| SYRE | 46.40% | $935.48M | -39.83% | 0.00% |
| RGNX | 44.02% | $434.35M | -20.33% | 0.00% |
| FDMT | 43.48% | $199.66M | -79.33% | 0.00% |
| XENE | 43.33% | $2.56B | -7.61% | 0.00% |
| CGON | 42.67% | $2.03B | -13.46% | 0.00% |
| RCKT | 42.39% | $310.29M | -85.62% | 0.00% |
| KYMR | 42.25% | $3.12B | +47.65% | 0.00% |
| DYN | 41.85% | $1.02B | -73.78% | 0.00% |
| COGT | 41.67% | $843.67M | -11.36% | 0.00% |
| BEAM | 41.63% | $2.00B | -15.33% | 0.00% |
| ALEC | 41.56% | $149.99M | -65.99% | 0.00% |
| PLRX | 41.49% | $73.66M | -88.66% | 0.00% |
| ZNTL | 41.15% | $89.22M | -64.37% | 0.00% |
| OCUL | 41.04% | $1.51B | +41.41% | 0.00% |
| TECH | 41.01% | $8.34B | -25.57% | 0.60% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| OXBR | <0.01% | $16.90M | +1.79% | 0.00% |
| FUBO | -0.02% | $1.25B | +178.63% | 0.00% |
| ASUR | -0.08% | $293.40M | +33.73% | 0.00% |
| KO | -0.14% | $305.22B | +11.97% | 2.81% |
| KMB | -0.14% | $43.92B | -3.75% | 3.75% |
| NOC | 0.26% | $71.81B | +14.14% | 1.69% |
| CNR | -0.27% | $3.86B | -28.77% | 0.95% |
| EQNR | -0.28% | $70.85B | -6.80% | 5.49% |
| CYD | 0.30% | $890.68M | +164.07% | 3.83% |
| DXCM | 0.32% | $32.77B | -24.64% | 0.00% |
| VHC | -0.52% | $48.19M | +108.24% | 0.00% |
| FATBB | -0.57% | $49.01M | -5.66% | 10.18% |
| LQDT | -0.63% | $753.04M | +21.88% | 0.00% |
| LRN | -0.68% | $5.99B | +100.06% | 0.00% |
| AEP | 0.72% | $55.16B | +17.93% | 3.54% |
| DQ | -0.74% | $1.18B | +11.88% | 0.00% |
| VSTA | 0.74% | $344.07M | +39.29% | 0.00% |
| RLX | -0.83% | $2.13B | +27.17% | 0.42% |
| CQP | 0.90% | $27.02B | +12.31% | 5.88% |
| CPSH | 0.92% | $42.27M | +74.25% | 0.00% |
